Bausch + Lomb Co. (NYSE:BLCO) Short Interest Update
Bausch + Lomb Co. (NYSE:BLCO – Get Free Report) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 3,840,000 shares, a growth of 10.0% from the October 31st total of 3,490,000 shares. Approximately 10.0% of the shares of the company are short sold. Based on an average daily trading volume, of 385,900 shares, the days-to-cover ratio is presently 10.0 days.
Institutional Trading of Bausch + Lomb
Institutional investors and hedge funds have recently bought and sold shares of the stock. Brandes Investment Partners LP increased its holdings in shares of Bausch + Lomb by 6.0% in the 1st quarter. Brandes Investment Partners LP now owns 104,062 shares of the company’s stock valued at $1,812,000 after purchasing an additional 5,935 shares during the period. Segantii Capital Management Ltd acquired a new position in shares of Bausch + Lomb in the 2nd quarter valued at about $6,021,000. Gabelli Funds LLC increased its holdings in shares of Bausch + Lomb by 4.0% in the 2nd quarter. Gabelli Funds LLC now owns 257,727 shares of the company’s stock valued at $5,173,000 after purchasing an additional 10,000 shares during the period. Coronation Fund Managers Ltd. increased its holdings in shares of Bausch + Lomb by 25.2% in the 1st quarter. Coronation Fund Managers Ltd. now owns 350,518 shares of the company’s stock valued at $6,103,000 after purchasing an additional 70,556 shares during the period. Finally, Hodges Capital Management Inc. increased its holdings in shares of Bausch + Lomb by 84.1% in the 2nd quarter. Hodges Capital Management Inc. now owns 527,991 shares of the company’s stock valued at $15,055,000 after purchasing an additional 241,152 shares during the period. Institutional investors and hedge funds own 12.45% of the company’s stock.
Wall Street Analyst Weigh In
BLCO has been the topic of a number of recent research reports. Barclays cut their target price on Bausch + Lomb from $19.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Evercore ISI assumed coverage on shares of Bausch + Lomb in a research note on Tuesday, October 3rd. They set an “outperform” rating and a $20.00 price objective on the stock. Morgan Stanley cut their price objective on shares of Bausch + Lomb from $20.00 to $18.50 and set an “equal weight” rating on the stock in a research note on Friday, October 13th. Finally, HC Wainwright cut their price objective on shares of Bausch + Lomb from $22.00 to $21.00 and set a “buy” rating on the stock in a research note on Friday, October 6th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Bausch + Lomb presently has an average rating of “Moderate Buy” and an average price target of $20.35.
Check Out Our Latest Stock Report on Bausch + Lomb
Bausch + Lomb Price Performance
BLCO traded up $0.04 during trading on Friday, reaching $15.45. The company had a trading volume of 398,586 shares, compared to its average volume of 286,289. The firm’s 50-day simple moving average is $16.33 and its 200 day simple moving average is $18.01. The company has a current ratio of 1.78, a quick ratio of 1.23 and a debt-to-equity ratio of 0.64. Bausch + Lomb has a 12-month low of $14.37 and a 12-month high of $21.95.
Bausch + Lomb (NYSE:BLCO – Get Free Report) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $990.68 million. Bausch + Lomb had a positive return on equity of 3.63% and a negative net margin of 5.22%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.31 EPS. As a group, equities analysts forecast that Bausch + Lomb will post 0.65 earnings per share for the current fiscal year.
About Bausch + Lomb (Get Free Report)
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Bausch + Lomb, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Bausch + Lomb wasn’t on the list.
While Bausch + Lomb currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to investing in 5G and which 5G stocks show the most promise.
Original: MarketBeat News Feed: Bausch + Lomb Co. (NYSE:BLCO) Short Interest Update